T細胞療法の世界市場:モダリティ別、療法別、疾患別

◆英語タイトル:T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 - 2026
◆商品コード:GV9NV057
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2019年9月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥642,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥750,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥966,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、T細胞療法の世界市場について調査・分析し、市場動向、モダリティ別(研究、商業化)分析、療法別(CAR T細胞療法、T細胞受容体(TCR)ベース、腫瘍浸潤リンパ球(TIL)ベース)分析、疾患別(血液悪性腫瘍、固形腫瘍)分析、地域別分析、競合動向などを含め次の構成でお届け致します。

・調査手法及び範囲
・エグゼクティブサマリー
・市場動向
・T細胞療法の世界市場:モダリティ別(研究、商業化)
・T細胞療法の世界市場:療法別(CAR T細胞療法、T細胞受容体(TCR)ベース、腫瘍浸潤リンパ球(TIL)ベース)
・T細胞療法の世界市場:疾患別(血液悪性腫瘍、固形腫瘍)
・T細胞療法の世界市場:地域別
・競合動向
【レポートの概要】

The global T-cell therapy market size is expected to reach USD 7.51 billion, expanding at a CAGR of 15.4% by 2026, according to a new report by Grand View Research, Inc. The landmark approvals of Yescarta and Kymriah have spurred unprecedented advancements in the market. The launch of these breakthrough therapies has bolstered cash inflow for innovation, thereby driving the growth.

Expansion of the market for T-cell therapy significantly relies on shifting preference from first-line stem cell transplants and chemotherapy to third-line CAR T-cell therapy. Moreover, the ever-expanding plethora of medical conditions for which the T cell therapies is projected to bode well for the market growth. Rise in oncological disorders is projected to drive interest as well as investments in the T-cell therapy market in near future.

In contrast with the small-molecule landscape, engineered T cells market landscape is distinguished by an extensive network that encompasses several entities marked by connections academically, financially, and via technology licensing. Research bodies, and manufacturers, and regulators engage in assessing the long-term efficacy and safety of therapies to ensure safe access to patients.

By far, the antigen challenge and linked toxicity concerns have impeded the development of CAR T therapies in non-hematological malignancies. Market players are applying a data-driven approach of exploring this space to mitigate the challenge and expand the usage of T-cell therapy in indication type such as brain cancer and melanoma.

Further key findings from the report suggest:

• In the coming years, the number of hospitals implementing CAR T therapies is expected to increase, thereby driving the commercialized business model

• Research-based business modality accounted for the highest revenue generation over the past years, attributed to the presence of several research programs

• CAR-T cell therapy market share accounted for the larger revenue share of the overall T-cell therapy market in 2018 owing to the highest investment by sponsors in this therapy type

• Presence of approved products for B cell lymphoma and acute lymphocytic leukemia has resulted in the dominance of hematological malignancies in the market

• Therapy for solid tumors is expected to emerge as the lucrative source of revenue generation in the forthcoming years

• Rising research activities in CAR T-cell therapy for solid tumors, particularly, for brain & central nervous system and melanoma, is expected to benefit the key players

• North America led the global market in 2018 owing to the presence of a large number of cancer centers engaging in research activities. Moreover, U.S.-based pharma companies like Pfizer Inc. and Celgene Corporation have shifted their focus from conventional drug development to T-cell therapy space

• Asia Pacific is estimated to witness the fastest growth with China at the forefront. China has surpassed the number of CAR T clinical trials conducted in U.S. Moreover, Novartis is strategizing to secure approval for Kymriah by China regulatory authorities in the forthcoming years

• Gilead Sciences, Novartis AG, TCR2 Therapeutics Inc., Celgene Corporation, Sorrento Therapeutics, bluebird bio, and Fate Therapeutics are some key players operating in the market. They engage in mergers and acquisitions with therapy developers. Acquisition of Juno Therapeutics by Celgene in January 2018 and Kite Pharma by Gilead in August 2017 are some notable examples of acquisitions in this market

【レポートの目次】

Table of content

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Competition Milieu
2.2 Market Snapshot
2.3 Segment Outlook
Chapter 3 Market Variables, Trends, & Scope
3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2018
3.2 T-Cell Therapy – Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
3.2.1.2 Growing competition among market players
3.2.1.3 Approval of Kymriah and Yescarta across various countries
3.2.1.4 Developments in CAR T-cell therapy for solid tumors
3.2.1.5 Technological advancements in manufacturing process
3.2.2 Market restraint analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.2.2.2 High prices of therapies
3.2.2.3 CAR T limitations
3.2.3 Opportunity analysis
3.2.3.1 Facility expansion for cell and gene therapies
3.2.3.2 Rising global financings in gene and cell therapy arena
3.2.3.3 Ongoing developments in viral & non-viral vector manufacturing arena
3.3 Regulatory Landscape
3.3.1 Current and potential future approvals
3.3.2 Frameworks for risk mitigation and safety monitoring
3.3.3 Regulatory framework, by geography
3.3.3.1 U.S.
3.3.3.2 Europe
3.3.3.3 China
3.3.3.4 Japan
3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
3.4.1 Insurance coverage
3.4.2 Value-based price benchmarks
3.4.3 Alternate payment strategies
3.5 Patent Landscape
3.6 Deals, Funding’s, Partnerships and Collaborations
3.6.1 Licensing deals
3.6.2 Merger & acquisition deals
3.6.3 Collaboration & partnerships
3.7 Pipeline Analysis
3.7.1 Clinical trial landscape
3.8 Geographic Mapping of Companies
3.9 Competitive Landscape for CD19­directed CAR­T Therapies and Other T-cell therapies
3.10 T-cell Therapy Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.10.1 Political landscape
3.10.2 Economic landscape
3.10.3 Social landscape
3.10.4 Technology landscape
3.11 Industry Analysis – Porter’s
3.11.1 Supplier bargaining power
3.11.2 Buyer bargaining power
3.11.3 Substitution threat
3.11.4 Threat from new entrant
3.11.5 Competitive rivalry
Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis
4.1 T-cell Therapy Market: Modality Movement Analysis
4.2 Research
4.2.1 Global research-based T-cell therapy market, 2015 – 2026 (USD Million)
4.3 Commercialized
4.3.1 Global commercial T-cell therapy market, 2015 – 2026 (USD Million)
Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
5.1 T-cell Therapy Market: Therapy Type Movement Analysis
5.2 CAR T-cell Therapy
5.2.1 Global CAR T-cell Therapy market, 2015 – 2026 (USD Million)
5.3 T Cell Receptor (TCR)-based
5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2015 – 2026 (USD Million)
5.4 Tumor Infiltrating Lymphocytes (TIL)-based
5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2015 – 2026 (USD Million)
Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis
6.1 T-cell Therapy Market: Indication Movement Analysis
6.2 Hematologic Malignancies
6.2.1 Global T-cell therapy market for hematologic malignancies, 2015 – 2026 (USD Million)
6.2.2 Lymphoma
6.2.2.1 Global T-cell therapy market for lymphoma, 2015 – 2026 (USD Million)
6.2.3 Leukemia
6.2.3.1 Global T-cell therapy market for leukemia, 2015 – 2026 (USD Million)
6.2.4 Myeloma
6.2.4.1 Global T-cell therapy market for myeloma, 2015 – 2026 (USD Million)
6.3 Solid Tumors
6.3.1 Global T-cell therapy market for solid tumors, 2015 – 2026 (USD Million)
6.3.2 Melanoma
6.3.2.1 Global T-cell therapy market for melanoma, 2015 – 2026 (USD Million)
6.3.3 Brain & Central Nervous System
6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2015 – 2026 (USD Million)
6.3.4 Liver cancer
6.3.4.1 Global T-cell therapy market for liver cancer, 2015 – 2026 (USD Million)
6.3.5 Others
6.3.5.1 Global T-cell therapy market for other cancer forms, 2015 – 2026 (USD Million)
Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Use-type & Therapy Type
7.1 T-cell Therapy Market Share by Regional, 2018 & 2026
7.2 North America
7.2.1 North America T-cell therapy market, 2015 – 2026 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.2.2.2 U.S. T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.2.2.3 U.S. T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.2.3 Canada
7.2.3.1 Canada T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.2.3.2 Canada T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.2.3.3 Canada T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.3 Europe
7.3.1 Europe T-cell therapy market, 2015 – 2026 (USD Million)
7.3.2 Germany
7.3.2.1 Germany T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.3.2.2 Germany T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.3.2.3 Germany T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.3.3 U.K.
7.3.3.1 U.K. T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.3.3.2 U.K. T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.3.3.3 U.K. T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.4 Asia Pacific
7.4.1 Asia Pacific T-cell therapy market, 2015 – 2026 (USD Million)
7.4.2 Japan
7.4.2.1 Japan T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.4.2.2 Japan T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.4.2.3 Japan T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.4.3 China
7.4.3.1 China T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.4.3.2 China T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.4.3.3 China T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.5 Latin America
7.5.1 Latin America T-cell therapy market, 2015 – 2026 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil T-cell therapy market, 2015 – 2026 (USD Million), by modality
7.5.2.2 Brazil T-cell therapy market, 2015 – 2026 (USD Million), by therapy type
7.5.2.3 Brazil T-cell therapy market, 2015 – 2026 (USD Million), by indication
7.6 MEA
7.6.1 MEA T-cell therapy market, 2015 – 2026 (USD Million)
7.6.2 South Africa
7.6.2.1 Brazil T-cell therapy market, 2016 – 2026 (USD Million), by modality
7.6.2.2 Brazil T-cell therapy market, 2016 – 2026 (USD Million), by therapy type
7.6.2.3 Brazil T-cell therapy market, 2016 – 2026 (USD Million), by indication
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Company Profiles
8.2.1 Novartis AG
8.2.1.1 Company overview
8.2.1.1.1 AveXis, Inc.
8.2.1.2 Financial performance
8.2.1.3 Product benchmarking
8.2.1.4 Strategic initiatives
8.2.2 Gilead Sciences
8.2.2.1 Company overview
8.2.1.1.1 Kite Pharma
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.4 Strategic initiatives
8.2.3 bluebird bio, Inc.
8.2.3.1 Company overview
8.2.3.2 Financial performance
8.2.3.3 Product benchmarking
8.2.3.4 Strategic initiatives
8.2.4 TCR2 Therapeutics Inc
8.2.4.1 Company overview
8.2.4.2 Financial performance
8.2.4.3 Product benchmarking
8.2.4.4 Strategic initiatives
8.2.5 Sorrento Therapeutics
8.2.5.1 Company overview
8.2.5.2 Product benchmarking
8.2.5.3 Strategic initiatives
8.2.6 Fate Therapeutics
8.2.6.1 Company overview
8.2.6.2 Financial performance
8.2.6.3 Product benchmarking
8.2.6.3 Strategic initiatives
8.2.7 Merck KGaA
8.2.7.1 Company overview
8.2.7.2 Financial performance
8.2.7.3 Product benchmarking
8.2.7.3 Strategic initiatives
8.2.8 Pfizer Inc.
8.2.8.1 Company overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.4 Strategic initiatives
8.2.9 Amgen
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.4 Strategic initiatives
8.2.10 Celgene Corporation
8.2.10.1 Company overview
8.2.1.1.1 Juno Therapeutics
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.4 Strategic initiatives

List of Tables

TABLE 1 Summary of finalized, proposed, and modeled payment adjustments, 2019 - 2023
TABLE 2 Licensing deals in T-cell therapy space
TABLE 3 Merger & acquisition deals in T-cell therapy space
TABLE 4 Collaboration & partnerships in T-cell therapy space
TABLE 5 CAR T-cell target antigens in US trials
TABLE 6 CAR T-cell target antigens in China trials
TABLE 7 Competitive landscape for CD 19-directed CAR T Therapies in r/r lymphoma and leukemia
TABLE 8 CAR T-cell targets under investigation for hematologic malignancies
TABLE 9 North America T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 10 North America T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 11 North America T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 12 North America T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 13 North America T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 14 U.S. T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 15 U.S. T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 16 U.S. T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 17 U.S. T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 18 U.S. T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 19 Canada T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 20 Canada T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 21 Canada T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 22 Canada T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 23 Canada T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 24 Europe T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 25 Europe T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 26 Europe T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 27 Europe T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 28 Europe T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 29 Germany T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 30 Germany T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 31 Germany T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 32 Germany T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 33 Germany T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 34 U.K. T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 35 U.K. T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 36 U.K. T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 37 U.K. T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 38 U.K. T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 39 Asia Pacific T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 40 Asia Pacific T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 41 Asia Pacific T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 42 Asia Pacific T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 43 Asia Pacific T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 44 Japan T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 45 Japan T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 46 Japan T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 47 Japan T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 48 Japan T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 49 China T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 50 China T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 51 China T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 52 China T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 53 China T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 54 Latin America T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 55 Latin America T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 56 Latin America T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 57 Latin America T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 58 Latin America T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 59 Brazil T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 60 Brazil T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 61 Brazil T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 62 Brazil T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 63 Brazil T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 64 MEA T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 65 MEA T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 66 MEA T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 67 MEA T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 68 MEA T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 69 South Africa T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
TABLE 70 South Africa T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
TABLE 71 South Africa T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 72 South Africa T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
TABLE 73 South Africa T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)

【レポートのキーワード】

T細胞療法、研究、商業化、CAR T細胞療法、T細胞受容体(TCR)ベース、腫瘍浸潤リンパ球(TIL)ベース、血液悪性腫瘍、固形腫瘍

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[T細胞療法の世界市場:モダリティ別、療法別、疾患別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆